Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Nuclear Cardiology’s Next Step

 Nuclear cardiology is on the dawn of a new technology—IQ•SPECT promises to reduce acquisition time, add hybrid or fusion imaging with CT and maximize efficiency in SPECT/CT scanning.

NOPR: A Landmark Study

Initial Results from National Oncologic PET Registry (NOPR) have been published recently in the Journal of Clinical Oncology. The results provide impressive evidence for the substantial impact of PET imaging across all cancers.

Evidence-based Medicine Points to Wider Role for Molecular Imaging in Patient Care

Evidence-based medicine has been embraced as a practice to increase healthcare expenditures and as a tool to improve patient care, ensuring that patients receive the best resources for their care, without unnecessary and wasteful procedures. Clinical results are proving molecular imaging’s merits in a wider number of applications. 

Changing Treatment Early Enough to Matter

This issue we are discussing several important topics in molecular imaging and medicine. One addresses the need for developing tools not only to monitor therapeutic responses, but also to stratify patients into the treatments that are most likely to result in significant responses. This concept can be applied not only to oncology, but also is highly relevant in patients with neurologic and cardiac diseases.

Assessing Cancer Therapy & Infection

This issue features several topics of critical importance in the field of imaging.

NIH launches collaborative effort to find biomarkers for Parkinson's

The National Institutes of Health (NIH) has launched the Parkinson’s Disease Biomarkers Program, which aims to accelerate the search for biomarkers in Parkinson's disease, in part by improving collaboration among researchers and helping patients get involved in clinical studies.

Amyvid nabs European Union approval

Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for PET imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment.

ASRT reports enrollment boom in nuke med, RT programs

The number of students entering nuclear medicine and radiation therapy programs increased in 2012, while enrollment in radiography programs dipped, according to the American Society of Radiologic Technologists (ASRT) Enrollment Snapshot of Radiography, Radiation Therapy and Nuclear Medicine Technology Programs. ASRT reported a mixed employment outlook, with approximately 40 percent of nuclear medicine graduates unemployed after graduation.